Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSarepta Therapeutics Inc

Sarepta Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
16.68 USD 0.26 ( 1.58%)
Last update at 2026-11-11T21:25:00Z
VOLUME
1999063
Market Cap
2188.59M

Momentum Score

…

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
16.16
Low
16.78
High
52 Week Price Range
14.68
Low
25.32
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Sarepta Therapeutics is a commercial-stage biotechnology company developing RNA-targeted and gene therapies for rare neuromuscular diseases, with a leading focus on Duchenne muscular dystrophy (DMD) and an approved exon-skipping franchise. Long-term growth may be supported by uptake of marketed DMD therapies, progress in its gene-therapy pipeline, and potential label expansions or geographic launches, which could appeal to investors seeking exposure to specialized genetic medicines.
Principal risks include significant clinical and regulatory uncertainty, reimbursement and pricing pressure, competition, and manufacturing and execution challenges that could materially affect prospects.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
16.42
Dividend Yield
-
Revenue TTM
1974.34M
Revenue Per Share
19.00
Gross Profit TTM
377.26M
Debt / Equity
0.91
ROE
-9.48%
Net Debt
238.46M
ROCE
-30.72%
Diluted EPS TTM
-1.57

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -702.23M 260.77M -520.10M -689.96M -418.95M
Net income -713.41M 235.24M -535.98M -703.49M -418.78M
Selling general administrative 478.94M 557.87M 481.87M 451.42M 282.66M
Selling and marketing expenses - - 28.60M - -
Gross profit 1316.73M 1582.88M 1092.99M 793.02M 604.84M
Reconciled depreciation 44.52M 37.72M 43.58M 41.86M 38.02M
Ebit -692.49M 279.17M -498.09M -536.20M -449.71M
Ebitda -647.97M 316.89M -453.69M -473.54M -412.12M
Depreciation and amortization 44.52M 37.72M 44.40M 62.67M 37.59M
Non operating income net other - - - - 40.76M
Operating income -657.77M 218.08M -267.82M -536.20M -449.71M
Other operating expenses 2856.01M 1683.90M 1511.16M 1469.21M 1151.60M
Interest expense 9.73M 18.39M 22.01M 53.25M 63.52M
Tax provision 11.19M 25.54M 29.10M 13.53M -0.17M
Interest income 36.69M 71.77M 67.66M 16.49M 0.35M
Net interest income -1.45M 53.38M 44.20M -36.76M -63.17M
Income tax expense 11.19M 25.54M 15.88M 13.53M -0.17M
Total revenue 2198.24M 1901.98M 1243.34M 933.01M 701.89M
Total operating expenses 1974.51M 1364.80M 1360.82M 1329.22M 1054.55M
Cost of revenue 881.50M 319.10M 150.34M 139.99M 97.05M
Total other income expense net -44.45M 42.69M -252.27M -153.76M 30.76M
Net income from continuing ops -713.41M 235.24M -690.88M -703.49M -418.78M
Net income applicable to common shares - - - -703.49M -418.78M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3349.70M 3963.17M 3264.58M 3128.37M 3147.97M
Intangible assets 28.95M 26.89M 29.62M 7.58M 14.24M
Other current assets 163.93M 318.98M 140.52M 7.72M 6.14M
Total liab 2209.08M 2435.43M 2405.24M 2743.42M 2219.97M
Total stockholder equity 1140.62M 1527.74M 859.34M 384.95M 928.01M
Other current liab 359.66M 356.12M 315.00M 419.00M 15.05M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -4876.98M -4210.97M -4446.21M -3910.24M -3206.75M
Other liab - - - 521.94M 628.84M
Other assets - - 0.00M 286.62M 292.95M
Cash 801.28M 1103.01M 428.43M 966.78M 2115.87M
Total current liabilities 1095.29M 731.68M 653.66M 619.60M 452.73M
Current deferred revenue 443.40M 130.26M 50.42M 89.24M 89.24M
Net debt 238.46M 240.06M 968.38M 650.58M -977.48M
Short term debt 11.39M 13.47M 123.33M 15.49M 271.70M
Short long term debt - - 105.48M - -
Short long term debt total 1039.74M 1343.07M 1396.81M 1617.36M 1138.39M
Other stockholder equity 6017.32M 5738.92M 5304.62M 4296.84M 4134.77M
Property plant equipment - - - 244.99M 191.16M
Total current assets 2537.94M 3073.46M 2579.33M 2557.86M 2604.10M
Long term investments 10.57M 136.87M 6.53M 31.32M 34.89M
Net tangible assets - - - 377.37M 913.77M
Short term investments 138.37M 251.78M 1247.82M 1022.60M 0.00M
Net receivables 519.61M 649.73M 439.71M 259.70M 171.64M
Long term debt 828.97M 1137.12M 1132.52M 1544.29M 1096.88M
Inventory 914.74M 749.96M 322.86M 203.97M 186.21M
Accounts payable 280.84M 214.44M 164.92M 95.88M 76.74M
Accumulated other comprehensive income 0.27M -0.22M 0.92M -1.66M -0.02M
Common stock total equity - - - - 0.01M
Retained earnings total equity - - - - -3206.75M
Non currrent assets other 311.15M 237.30M 276.41M 286.62M 143.28M
Non current assets total 811.76M 889.71M 685.24M 570.50M 543.88M
Capital lease obligations 210.77M 205.95M 158.81M 57.58M 41.51M
Long term debt total - - - - 1096.88M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 5.39M 755.56M -91.65M -1046.88M 436.01M
Change to liabilities - - - 58.33M -89.24M
Total cashflows from investing activities 69.64M 755.56M -165.80M -1046.88M 495.41M
Net borrowings -162.59M -0.07M 0.00M 304.17M 304.17M
Total cash from financing activities -168.34M 124.81M 125.00M 232.51M 561.57M
Change to operating activities - - - 14.62M 103.20M
Net income -713.41M 235.24M -535.98M -703.49M -418.78M
Change in cash -304.18M 674.58M -541.79M -1139.72M 613.81M
Begin period cash flow 1118.59M 444.01M 985.80M 2125.52M 1511.71M
End period cash flow 814.41M 1118.59M 444.01M 985.80M 2125.52M
Total cash from operating activities -205.48M -205.79M -500.99M -325.35M -443.17M
Issuance of capital stock 20.00M 0.00M 0.00M 0.00M 548.53M
Depreciation 44.52M 37.72M 44.40M 41.86M 38.02M
Other cashflows from investing activities -253.69M -10.00M 90.76M -2.43M 97.89M
Change to inventory -301.09M -395.17M -147.71M -50.78M -83.77M
Change to account receivables 203.75M -201.66M -185.70M -61.64M -51.65M
Sale purchase of stock -25.01M 0.00M 0.00M - 20.80M
Other cashflows from financing activities -17.06M 124.87M 125.00M 1025.70M 13.04M
Change to netincome - - - 375.75M 31.63M
Capital expenditures 101.97M 146.96M 87.34M 30.82M 38.49M
Change receivables - - - - -51.65M
Cash flows other operating - - - - 130.62M
Cash and cash equivalents changes - - - - 613.81M
Change in working capital 78.04M -716.61M -481.09M -39.47M -98.17M
Stock based compensation 123.40M 184.30M 182.51M 233.02M 113.94M
Other non cash items 261.98M 53.56M 289.16M 142.73M -94.00M
Free cash flow -307.45M -352.74M -588.34M -356.17M -481.66M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SRPT
Sarepta Therapeutics Inc		 0.26
1.58%		 16.68 - 20.92 1.11 1.43 1.24 16.91
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

215 First Street, Cambridge, MA, United States, 02142

617 274 4000

https://www.sarepta.com

835

Name Title Year Born
Mr. Douglas S. Ingram Esq. Pres, CEO & Director 1963
Mr. Ian Michael Estepan Exec. VP & CFO 1976
Mr. William F. Ciambrone Exec. VP of Technical Operations 1964
Dr. Louise R. Rodino-Klapac Ph.D. Exec. VP, Chief Scientific Officer and Head of R&D 1978
Mr. Ryan E. Brown Sr. VP, Gen. Counsel & Corp. Sec. 1978
Bilal Arif Sr. VP of Strategy and Operations NA
Mary Jenkins Sr. Mang. of Investor Relations NA
Ms. Alison Nasisi Chief People Officer & VP NA
Dr. Diane L. Berry Sr. VP of Global Health Policy and Gov. & Patient Affairs NA
Mr. Dallan Murray Sr. VP & Chief Customer Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…